Phase I Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 20 May 2014
At a glance
- Drugs Plerixafor (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 16 May 2012 Actual end date (1 Sep 2011) added as reported by ClinicalTrials.gov.
- 16 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2011 Planned end date changed from 1 Sep 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.